Crescent Biopharma (CBIO) Current Assets (2013 - 2026)

Crescent Biopharma (CBIO) has 14 years of Current Assets data on file, last reported at $195.6 million in Q1 2026.

• Current Assets for Q1 2026 came in at $195.6 million, up 3163.64% year-over-year; the trailing twelve-month figure through Mar 2026 was $195.6 million (up 3163.64% YoY), and the FY2025 annual result was $236.7 million, up 579.96% from the prior year.
• Current Assets fell to $195.6 million in Q1 2026 per CBIO's latest filing, from $236.7 million in the prior quarter.
• Over five years, Current Assets peaked at $236.7 million in Q4 2025 and troughed at $6.0 million in Q1 2025.
• A 5-year average of $76.6 million and a median of $53.8 million in 2022 frame the typical range for Current Assets.
• The sharpest annual moves came in 2025 and 2026: Current Assets plunged 81.99% in 2025, then surged 3163.64% in 2026.
• A 5-year view of Current Assets shows it stood at $50.7 million in 2022, then decreased by 13.65% to $43.8 million in 2023, then declined by 20.52% to $34.8 million in 2024, then soared by 579.96% to $236.7 million in 2025, then slipped by 17.36% to $195.6 million in 2026.
• Business Quant data shows CBIO's Current Assets at $195.6 million in Q1 2026, $236.7 million in Q4 2025, and $134.6 million in Q3 2025.